What happened: On July 10, 2026, China’s National Health Commission (NHC, 国家卫生健康委员会) publicly disclosed 28 substantiated research-misconduct cases from its health and medical research system, drawn from hospitals and institutions in Shanxi, Jiangxi, and Guangdong provinces, Chongqing municipality, and the Guangxi Zhuang and Xinjiang Uygur autonomous regions. The disclosure grouped the cases into three misconduct categories: data fabrication, “paper trading” (the buying, selling, or brokering of research data, manuscripts, or authorship positions), and guest authorship (crediting individuals who did not substantively contribute to the work).
The disclosure in detail
Per China Daily’s reporting on the NHC notice, one representative case involved researchers at Shanxi Bethune Hospital who traded experimental data that was later used in a paper published in an international journal in March 2022. Sanctions described in the disclosure include multi-year debarment from participating in government-funded research projects (three to ten years, depending on the case) and disqualification from serving as peer reviewers (three to five years). Retraction Watch flagged the NHC notice and China Daily’s coverage of it in its July 18, 2026 “Weekend reads” roundup, corroborating both the 28-case figure and the three misconduct categories.
The NHC’s own notice is published on its website (nhc.gov.cn), though the page sits behind bot-mitigation that blocks automated retrieval; this summary relies on the two independent secondary sources above, both of which cite the NHC disclosure directly and by name.
Why “paper trading” is the term to watch
“Paper trading” is not a typo for financial paper-trading — it is a direct rendering of a Chinese-language term (often 论文买卖 / 数据买卖, “trading of papers/data”) used by Chinese regulators and integrity bodies to describe the underground market in fabricated or purchased research outputs: data sets sold for insertion into a paper, manuscripts sold outright, or co-authorship slots sold to individuals who did no work on the study. It sits squarely inside what CASRAI and others track under the broader paper mill phenomenon — commercial operations that manufacture or broker fraudulent research content for a fee — though the NHC’s framing treats “trading” of authorship and data as its own distinct enforcement category alongside outright fabrication.
The “guest authorship” category maps onto what CASRAI’s dictionary defines under the related concept of ghost authorship and its inverse — crediting a contributor who did not meet authorship criteria in exchange for payment, favor, or institutional benefit, distinct from genuinely undisclosed ghostwriting. Readers new to the distinction may find the comparison useful: Ghost Authorship vs. Gift Authorship.
Why this matters for research-integrity offices outside China
Three things make this disclosure relevant beyond China’s own system:
- It’s a rare quantified, government-level disclosure. Most national health/science ministries do not publish aggregate misconduct-case counts with this level of categorical detail (case count, misconduct type, sanction range, institutional geography) on a routine cadence. NHC’s practice gives research-integrity offices and journal editors elsewhere a comparison point for what a systematic institutional-level disclosure regime can look like.
- It corroborates independent paper-mill research. Sleuthing and paper-mill research (including COPE’s ongoing work, see CASRAI’s coverage of COPE’s relaunched Paper Mills Working Group) has long identified China-linked medical-authorship-for-sale markets as a significant share of the global paper-mill problem. A government body naming “paper trading” and “guest authorship” as enforcement categories, rather than solely academic third-party detection, is a data point for that broader picture — not proof of overall scale, but consistent with it.
- It’s a due-diligence signal for co-authors, editors, and funders. Institutions and journals evaluating manuscripts or grant applications with co-authors or data drawn from the flagged institutions and provinces have a concrete, dated, named-source disclosure to reference if a specific paper or collaborator later comes under question — more useful than a general country-level risk heuristic.
What this disclosure does not establish
The 28 cases are a disclosed, sanctioned subset — not a measure of total misconduct incidence in China’s health research system, and not evidence that any specific unnamed researcher, institution, or paper outside the disclosed cases is implicated. CASRAI could not independently retrieve the NHC’s original notice text (see verification note above) and relies on China Daily’s and Retraction Watch’s reporting for the specifics in this article; readers citing exact figures or sanction lengths for their own institutional purposes should verify against the primary NHC notice or a further-confirmed English-language source before relying on them for formal case documentation.
